Fibrinolysis and atherogenesis in the JCR:LA-cp rat in relation to insulin and triglyceride concentrations in blood

Diabetologia

Volumn 41, Issue 2, 1998, Pages 141-147

  Schneider, D J ^a   Absher, P M ^a   Neimane, D ^a   Russell, J C ^b   Sobel, B E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Atherosclerosis; Diabetes; Hyperinsulinaemia; Hypertriglyceridaemia; Plasminogen activator inhibitor 1

Indexed keywords

GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FIBRINOLYSIS; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

AGING; ANIMALS; AORTA; ARTERIOSCLEROSIS; BLOOD GLUCOSE; FEMALE; FIBRINOLYSIS; INSULIN; MALE; OBESITY; ORGAN CULTURE TECHNIQUES; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, MUTANT STRAINS; SEX FACTORS; TRIGLYCERIDES;

EID: 0031934994     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050882     Document Type: Article

References (35)

1. Schneider DJ, Nordt TK, Sobel BE (1993) Attenuated fibrinolysis and atherogenesis in type II diabetic subjects. Diabetes 42: 1-7
2. Negri M, Sheiban I, Arigliano PL, et al. (1993) Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor-1. Am J Cardiol 72:397-401
3. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I (1994) Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemostas 72:44-53
4. Lupu F, Bergonzelli GE, Heim DA, et al. (1993) Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 13: 1090-1100
5. Padró T, Emeis JJ, Steins M, Schmid KW, Kienast J (1995) Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 15:893-902
6. Schleef RR, Loskutoff DJ, Podor TJ (1991) Immunoelectron microscopic localization of type 1 plasminogen activator inhibitor on the surface of activated endothelial cells. J Cell Biol 113: 1413-1423
7. Vague P, Juhan-Vague I, Aillaud MF, et al. (1986) Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 35:250-253
8. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE (1994) Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43:104-109
9. Landin K, Stigendal L, Eriksson E, et al. (1990) Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39: 1044-1048
10. Jansson JH, Johansson B, Boman K, Nilsson TK (1991) Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med 229:309-316
11. Dolphin PJ, Stewart B, Amy RM, Russell JC (1987) Serum lipids and lipoproteins in the atherosclerosis prone LA/N-corpulent rat. Biochim Biophys Acta 919: 140-148
12. Russell JC, Graham S, Hameed M (1994) Abnormal insulin and glucose metabolism in the JCR:LA-corpulent rat. Metabolism 43: 538-543
13. Russell JC, Koeslag DG, Amy RM, Dolphin PJ (1989) Plasma lipid secretion and clearance in hyperlipidaemic JCR:LA-corpulent rats. Arteriosclerosis 9: 869-876
14. Russell JC, Amy RM (1986) Early atherosclerotic lesions in a susceptible rat model: the LA/N-corpulent rat. Atherosclerosis 60: 119-129
15. Trinder P (1969) Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen oxygen acceptor. J Clin Path 22: 158-161
16. Bucolo, G, David H (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19: 476-487
17. Sawdey M, Podor TJ, Loskutoff DJ (1989) Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. J Biol Chem 264: 10396-10401
18. Chmielewska J, Wiman B (1986) Determination of tissue plasminogen activator and its "fast" inhibitor in plasma. Clin Chem 32:482-485
19. Angles-Cano E (1984) A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-t-PA) for high-fibrin-affinity tissue plasminogen activators. Anal Biochem 153:201-210
20. Ellis V, Dano K (1992) The urokinase receptor and the regulation of cell surface plasminogen activation. Fibrinolysis 6(S4):27-32
21. He CS, Wilhelm SM, Pentland AP, et al. (1989) Tissue co-operation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 86:2632-2637
22. Chapman HA Jr, Stone OL (1989) Co-operation between plasmin and elastase degradation by intact murine macrophages. Biochem J 222: 721-725
23. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K (1993) Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36:1175-1184
24. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon RR (1990) Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 120: 672-676
25. Ronnemaa T, Laakso M, Puukka P, Kallio V, Pyorala K (1988) Atherosclerotic vascular disease in middle aged insulin-treated, diabetic patients: association with endogenous insulin secretion capacity. Arteriosclerosis 8:237-240
26. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR (1990) Slow glucose removal rate and hyperinsulinaemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Int Med 113: 909-915
27. Farhat MY, Lavigne MC, Ramwell PW (1996) The vascular protective effects of estrogen. FASEB J 10:615-624
28. Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, Cefalu WT (1996) The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism 45:1254-1262
29. Schneider DJ, Sobel BE (1996) Synergistic augmentation of expression of PAI-1 induced by insulin, VLDL, and fatty acids. Coronary Artery Disease 7:813-817
30. Kooistra T, Bosma PJ, Tons HAM, Van Den Berg AP, Meyer P, Princen HMG (1989) Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas 62:723-728
31. Samad F, Yamamoto K, Loskutoff DJ (1996) Distribution and regulation of plasminogen activator inhibitor type-1 in murine adipose tissue in vivo. J Clin Invest 97:37-46
32. Torr-Brown SR, Sobel, BE (1994) Plasminogen activator inhibitor is elevated in plasma and diminished in platelets in patients with diabetes mellitus. Thromb Res 75:473-477
33. Nordt TK, Sawa H, Fujii S, Sobel BE (1995) Augmentation of plasminogen ativator inhibitor type 1 (PAI-1) by proinsulin and insulin in vivo. Circulation 91:764-770
34. Schneider DJ, Absher PM, Ricci MA (1997) The dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells. Circulation (in press)
35. Gebara OC, Mittleman MA, Sutherland P, et al. (1995) Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 91:1952-1958